100488-87-7

Pale-Yelow Solid

Competitive PAF receptor antagonist. Inhibits PAF induced human platelet aggregation. Inhibits PAF induced hypotension and lethality.

CV-6209 is a potent antagonist of the platelet-activating factor (PAF) receptor, inhibiting aggregation of rabbit and human platelets induced by PAF with IC₅₀ values of 75 and 170 nM, respectively. It has little action on platelet aggregation induced by arachidonic acid, ADP, or collagen. CV-6209 is bioavailable, as it prevents PAF-induced hypotension in rats, while not blocking hypotension triggered by arachidonic acid , histamine, bradykinin , or isoproterenol . CV-6209 is used to study the role of PAF receptor signaling in vitro and in vivo.

[1] Z TERASHITA. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo.[J]. Journal of Pharmacology and Experimental Therapeutics, 1987, 242 1: 263-268.
[2] H. S. LEONG. Vimentin autoantibodies induce platelet activation and formation of platelet-leukocyte conjugates via platelet-activating factor[J]. Journal of Leukocyte Biology, 2007, 83 2: 263-271. DOI: 10.1189/jlb.0607339
[3] SILVIA MUSIO. Anaphylaxis to a self-peptide in the absence of mast cells or histamine[J]. Laboratory Investigation, 2009, 89 4: 398-405. DOI: 10.1038/labinvest.2009.4